Collective Laboratory
Table of Contents
Collective Laboratory is a biotechnology company focused on developing adn commercializing novel diagnostic tests for infectious diseases. Founded in 2021, the company leverages innovative molecular biology techniques too create rapid, accurate, and affordable solutions for detecting pathogens. Their core technology centers around a proprietary nucleic acid amplification method designed for point-of-care diagnostics.
company Overview
Collective Laboratory aims to address the critical need for accessible and timely infectious disease testing, particularly in resource-limited settings. The company’s initial focus is on respiratory infections, including influenza, COVID-19, and respiratory syncytial virus (RSV). They are expanding their pipeline to include tests for sexually transmitted infections (STIs) and other prevalent pathogens. Collective Laboratory operates wiht a commitment to scientific rigor,quality control,and global health impact.
Technology Platform
At the heart of Collective Laboratory’s innovation is a novel nucleic acid amplification technology. Unlike traditional PCR (Polymerase Chain reaction) methods,their platform is designed for simplicity and speed,enabling results to be obtained in under 30 minutes. This rapid turnaround time is crucial for informed clinical decision-making and effective disease management. The technology is also engineered to be more robust and less susceptible to errors, improving diagnostic accuracy. Collective Laboratory Technology
Products and Pipeline
Currently, collective laboratory offers a multiplex PCR test for the simultaneous detection of influenza A/B, RSV, and SARS-CoV-2. This test is designed for use in clinical laboratories and point-of-care settings. The company is actively developing additional tests, including:
- A rapid test for Group A Streptococcus (Strep Throat)
- A panel for common STIs, including chlamydia, gonorrhea, and trichomoniasis
- A diagnostic assay for tuberculosis (TB)
Funding and Partnerships
Collective Laboratory has secured important funding from venture capital firms and government grants. In November 2023, the company announced a $20 million Series A funding round led by Venrock, with participation from existing investors. Press Release They have also established partnerships with several hospitals and clinics to evaluate and deploy their diagnostic tests.
Key Takeaways
- Collective Laboratory is a biotechnology company developing rapid diagnostic tests for infectious diseases.
- Their proprietary technology offers faster and more accurate results compared to traditional methods.
- The company is focused on addressing unmet needs in infectious disease diagnostics, particularly in resource-limited settings.
- Collective Laboratory has secured substantial funding and established strategic partnerships to accelerate its growth.
publication Date: 2025/11/20 11:58:34